Purchase Order HHSN269201800249P

<p>The National Institute of Neurological Disorders and Stroke awarded a purchase order to Illumina, Inc. valued at $16,189.27 on July 31, 2018, with ultimate completion on July 30, 2019. The order is firm fixed price with no set-aside. Work is performed in San Diego, California. The purchase order procures sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core offerings to federal health and research agencies.</p>

<p>The National Institute of Neurological Disorders and Stroke issued a $26,597.20 delivery order to Illumina, Inc. on August 19, 2020, for genetic sequencing and genomic analysis equipment and consumables.</p> <p>Place of performance is Bethesda, MD. The order was firm fixed price with no set-aside designation and an ultimate completion date of September 2, 2020. The source does not name a parent IDIQ or GWAC vehicle for this delivery order.</p>

The Department of Health and Human Services National Institutes of Health National Institute of Neurological Disorders and Stroke awarded a $292,320 firm fixed price delivery order to Illumina, Inc. for eighteen NOVASEQ X SERIES 25B REAGENT KITS (300 CYCLES). The place of performance is Chevy Chase, Maryland and the completion date is August 26, 2024. Illumina is a manufacturer and provider of sequencing and array-based solutions for genetic and genomic analysis. This delivery order was issued...

<p>The National Institute of Neurological Disorders and Stroke issued a delivery order to Illumina, Inc. on September 20, 2017, for an Infinium OmniExpressExome-8 V1.4 kit (16-sample and 48-sample configurations) with a ceiling value of $8,182.85.</p> <p>Place of performance is Bethesda, MD 20892. The order, priced on a firm fixed-price basis, has an ultimate completion date of September 2, 2020. No set-aside was applied.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. valued at $19,792.44 on August 15, 2018, for DNA and RNA sequencing instruments, reagents, consumables, and bioinformatics software. Performance is at North Bethesda, Maryland, with an ultimate completion date of September 14, 2018. The order carries firm fixed price terms and no set-aside designation.</p>

<p>The National Institutes of Health Office of Logistics and Acquisition Operations awarded a purchase order to Illumina, Inc. for $13,293.26 on September 1, 2016, with ultimate completion on July 16, 2017. Performance occurs in Bethesda, Maryland. The order covers biotechnology sequencing instruments, reagents, consumables, or bioinformatics software. No set-aside applied.</p>

<p>The National Institutes of Health Clinical Center awarded a purchase order to Illumina, Inc. for $75,560.00 on March 27, 2018, with ultimate completion on April 28, 2019. Place of performance is Bethesda, Maryland. The order calls for DNA and RNA sequencing instruments, reagents, consumables, or bioinformatics software under firm fixed price. No set-aside was used.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. for $17,735.76 on December 21, 2018, with completion by December 25, 2019. The order is a firm fixed price acquisition with no set-aside. Work is performed at Bethesda, Maryland. The purchase order procures DNA and RNA sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core product lines serving federal health and research agencies.</p>

<p>The National Institute of Nursing Research awarded a purchase order to Illumina, Inc. for $24,418.80 on November 30, 2018. The order is firm fixed price with no set-aside and carries an ultimate completion date of December 28, 2018. Place of performance is San Diego, California. The purchase order covers sequencing instruments, reagents, consumables, or bioinformatics software consistent with Illumina's core product portfolio in DNA and RNA sequencing technologies.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. for $15,314.69 on August 23, 2017, with an ultimate completion date of September 22, 2017. Work is performed in North Bethesda, Maryland. The order covers sequencing reagents and consumables under firm fixed price terms. No set-aside applied.</p>